About 50 million people worldwide suffer from epilepsy, a common neurological condition.¹ Recent developments have demonstrated that epilepsy is a complicated network failure involving several brain areas rather than just a localized illness.² Studies using functional neuroimaging have revealed changes in connection patterns that contribute to the epileptic state, such as hyperconnectivity in certain networks and hypoconnectivity in others. Different types of epilepsy are caused by these disturbances in network dynamics, which are also linked to treatment resistance and cognitive deficits.³ Conventional anti-seizure drugs may not treat the underlying network dysfunctions, but they frequently target neuronal excitability.⁴ These strategies include neuromodulation methods that seek to normalize abnormal network activity, such as transcranial magnetic stimulation and deep brain stimulation.⁵ Furthermore, individualized therapy regimens that target certain network disorders are becoming possible because to developments in precision medicine that make use of genetic and neuroimaging data. Developing more focused and efficient treatment approaches requires an understanding of the brain network dysfunctions associated with epilepsy. People with epilepsy, especially those with drug-resistant forms, may benefit from better results if network neuroscience concepts are incorporated into therapeutic treatment. Clarifying the intricate network linkages in the epileptic brain and utilizing these discoveries to develop novel treatment approaches should be the main goals of future study.

Understanding this malfunction is essential to creating effective treatments for epilepsy, a complicated neurological illness marked by a breakdown of normal neural circuit balance. The primary characteristic of epilepsy is neural network dysfunction, which includes aberrant synchronization, neuronal hyperexcitability, glial activation, neuroinflammation, oxidative stress, and mitochondrial dysfunction. These factors all work together to cause seizures.⁶ According to research, epileptic convulsions spread via dispersed networks such as the hippocampus, thalamocortical loops, and cortical-subcortical circuits rather of being localized in a single area of the brain.⁷ Abnormalities at the network level impact behaviour, cognition, and response to therapy, especially in cases of drug-resistant epilepsy.⁸ A major factor at the cellular level is an imbalance between excitation and inhibition; a dysregulation of glutamatergic excitatory and GABAergic inhibitory transmission causes hyperexcitable neurons and synchronous firing, which in turn causes seizures.⁹ Glial cells, like as astrocytes and microglia, are important regulators of network failure. In addition to maintaining neuroinflammation, activated glial cells also increase neuronal excitability and network hypersynchrony by releasing pro-inflammatory cytokines and chemokines.¹⁰ Other important factors include mitochondrial malfunction and oxidative stress. Reactive oxygen species (ROS) are produced during seizures, which damages neurons and kills cells. Mitochondrial dysfunction exacerbates network instability and epileptogenic by interfering with calcium homeostasis and energy metabolism. All things considered, neural network dysfunction in epilepsy is a complex process that includes disturbances at the cellular, synaptic, and network levels. Comprehending these systems serves as a basis for precision medicine tactics, neuromodulation techniques, and tailored medicines.^11,12 An integrated overview of these interacting mechanisms and their therapeutic targets is shown in Figure 2. Key preclinical mechanism–therapy–outcome relationships are summarised in Table 1.

A key component of brain network dynamics and a key factor in epilepsy is synaptic plasticity. Changes in long-term depression (LTD) and long-term potentiation (LTP) brought on by epileptic episodes upset the regular equilibrium between synaptic strengthening and weakening. Both prolonged seizure susceptibility and network hyperexcitability are influenced by abnormal LTP/LTD. Both diffuse and localized brain areas, such as the cortex and hippocampus, undergo structural and functional network remodelling. Axonal sprouting, altered synaptic connection, and loss or hypertrophy of the dendritic spine are among the changes that influence network dynamics and seizure propagation. Patients with epilepsy frequently have memory loss, learning disabilities, and behavioural comorbidities as a result of these structural and functional changes, which have direct cognitive and behavioural effects. Developing tailored therapeutics to restore normal connectivity and cognitive function requires an understanding of the interaction between synaptic plasticity and network remodelling.²⁵

Anti-seizure drugs have historically been the mainstay of epilepsy therapy; however, new therapeutic approaches have been made possible by a better knowledge of network breakdown, oxidative stress, neuroinflammation, and synaptic plasticity. These emerging molecular and network-directed approaches are summarised in Figure 3. These methods seek to lessen cognitive impairments, preserve neural circuits, and restore synaptic plasticity in addition to suppressing seizures.²⁶ Representative clinical phenotypes, dominant mechanisms, and corresponding therapies are outlined in Table 2.

It is becoming more widely acknowledged that epilepsy is a condition of neural network malfunction, with abnormal synaptic plasticity, glial cell activation, and neuronal synchronization. Cognitive deficits and behavioural comorbidities are among the ictal and interictal signs that are caused by these pathophysiological alterations . Antiepileptic medications (AEDs) are readily available, yet there are still large treatment gaps worldwide, especially in low- and middle-income nations. Delays in diagnosis, poor treatment optimization, and restricted access to healthcare are the main causes of these disparities. Furthermore, the underlying network dysfunctions and related cognitive deficiencies are frequently ignored by modern AEDs, which exclusively target seizure management. New developments in network-based methods, such as the use of graph theory and neuroimaging techniques, provide encouraging paths for comprehending and addressing the damaged brain circuits in epilepsy. Furthermore, new treatment approaches that target neuroinflammation, mitochondrial function, and oxidative stress management seek to offer neuroprotective benefits outside of the realm of conventional AEDs. The creation of precision medicine strategies that combine network-level insights with customized treatment regimens should be the main focus of future research. In order to restore normal network function and enhance long-term results for people with epilepsy, this involves investigating new pharmacological treatments, gene-based therapies, and neuromodulation approaches. In conclusion, filling the existing therapy gaps and developing therapeutic approaches that focus on the underlying pathophysiology of the condition require a thorough knowledge of the neural network dysfunctions in epilepsy.

AEDs – Antiepileptic Drugs

ASDs – Antiseizure Drugs

ATP – Adenosine Triphosphate

BBB – Blood–Brain Barrier

CA – Cornu Ammonis (Hippocampal Region)

CNS – Central Nervous System

COX – Cyclooxygenase

CRISPR – Clustered Regularly Interspaced Short Palindromic Repeats

CoQ10 – Coenzyme Q10

DBS – Deep Brain Stimulation

DNA – Deoxyribonucleic Acid

EEG – Electroencephalography

EGCG – Epigallocatechin Gallate

FDA – Food and Drug Administration

GABA – Gamma-Aminobutyric Acid

GLUT – Glucose Transporter

HS – Hippocampal Sclerosis

IL-1β – Interleukin-1 Beta

IL-6 – Interleukin-6

ILAE – International League Against Epilepsy

KA – Kainic Acid

LTP – Long-Term Potentiation

LTD – Long-Term Depression

MMPs – Matrix Metalloproteinases

MRI – Magnetic Resonance Imaging

mRNA – Messenger Ribonucleic Acid

mtDNA – Mitochondrial DNA

NAC – N-Acetylcysteine

NF-κB – Nuclear Factor Kappa B

NMDAR – N-Methyl-D-Aspartate Receptor

PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PTZ – Pentylenetetrazol

RCTs – Randomized Controlled Trials

ROS – Reactive Oxygen Species

SOD – Superoxide Dismutase

TLE – Temporal Lobe Epilepsy

TNF-α – Tumor Necrosis Factor Alpha

VNS – Vagus Nerve Stimulation

WHO – World Health Organization